Abstract-We previously showed that CGP 42112 (an angiotensin type 2 [AT 2 ] agonist) markedly reduces catecholamine biosynthesis by decreasing cGMP production mediated by AT 2 , a subtype of Ang II receptor that is dominantly expressed in cultured porcine chromaffin cells. To elucidate the relationship of the 2 types of Ang II receptors, angiotensin type 1 (AT 1 ) and AT 2 , in the synthesis of catecholamine in adrenal medullary cells, we have examined the effect of Ang II plus CV-11974 (an AT 1 antagonist that selectively simulates AT 2 stimulation) and the effect of Ang II plus PD 123319 (an AT 2 antagonist that selectively simulates AT 1 stimulation) on catecholamine synthesis. We found that Ang II reduced cGMP production via AT 2 , in a similar manner to that found with CGP 42112. Stimulation of AT 1 significantly upregulated protein kinase C activity. Tyrosine hydroxylase (TH) is a rate-limiting enzyme involved in the biosynthesis of catecholamine, and this catecholamine synthesis depends both on TH enzyme activity and on the levels of TH protein after TH gene transcription. We found that AT 2 stimulation significantly inhibited TH enzyme activity, whereas AT 1 stimulation significantly upregulated TH enzyme activity. The stimulatory effect of AT 1 was completely inhibited by Ro-32-0432 (a protein kinase C inhibitor) and PD 98059 (a MAP kinase kinase-1 [MEK-1] inhibitor). Pretreatment of cells with either 8-Br-cGMP (a membrane-permeable cGMP analog) or Zaprinast (a phosphodiesterase inhibitor) abolished the inhibitory effect of AT 2 on TH enzyme activity, indicating that the stimulatory effect of AT 2 may be mediated through a reduction in cGMP concentration. Similar to the effect on TH enzyme activity, AT 2 stimulation significantly reduced TH mRNA and protein levels and net catecholamine content below basal levels, whereas AT 1 stimulation increased them. We confirmed these findings by gel mobility shift assay. Our results show that stimulation of AT 2 reduces catecholamine biosynthesis via a decrease in cGMP levels. In contrast, stimulation of AT 1 stimulates catecholamine biosynthesis through activation of PKC. Thus, we conclude that AT 1 and AT 2 have counter-regulatory roles in the synthesis of catecholamine in adrenal medullary chromaffin cells. Key Words: receptors, angiotensin II Ⅲ tyrosine hydroxylase Ⅲ cyclic GMP Ⅲ angiotensin antagonist Ⅲ catecholamines T here are 2 major subtypes of Ang II receptor, type 1 (AT 1 ) and type 2 (AT 2 ). 1 Most of the stimulatory effects of Ang II, such as those on the cardiovascular system and on fluid volume homeostasis, are mediated by AT 1 . AT 1 is linked with activation of phospholipase C and with a subsequent increase in [Ca 2ϩ ] i and protein kinase C (PKC) activity. 1 In contrast, the physiological role of and signal transduction pathways connected with AT 2 are not established. In adults, AT 2 expression is restricted to only a few organs, such as adrenal medulla. 2 It has been shown that stimulation of AT 2 induces a decrease in intracellular cGMP levels in neuronal cells. 3, 4 However, the physiological roles of AT 2 in adrenal chromaffin cells remain to be clarified.
T here are 2 major subtypes of Ang II receptor, type 1 (AT 1 ) and type 2 (AT 2 ). 1 Most of the stimulatory effects of Ang II, such as those on the cardiovascular system and on fluid volume homeostasis, are mediated by AT 1 . AT 1 is linked with activation of phospholipase C and with a subsequent increase in [Ca 2ϩ ] i and protein kinase C (PKC) activity. 1 In contrast, the physiological role of and signal transduction pathways connected with AT 2 are not established. In adults, AT 2 expression is restricted to only a few organs, such as adrenal medulla. 2 It has been shown that stimulation of AT 2 induces a decrease in intracellular cGMP levels in neuronal cells. 3, 4 However, the physiological roles of AT 2 in adrenal chromaffin cells remain to be clarified.
In adrenal medullary cells, tyrosine hydroxylase (TH) is a rate-limiting enzyme involved in the biosynthesis of catecholamines. TH activity can be regulated by both short-term and long-term mechanisms. Short-term regulation of enzyme activity occurs at the posttranscriptional level, where phosphorylation of TH leads to its activation. 5 Long-term regulation occurs after TH gene transcription at the level of protein synthesis. 5 Recently, it has been shown that the cGMP/ cGMP-dependent protein kinase (PKG) pathway plays an important role in catecholamine biosynthesis. 6 -10 Indeed, agents that increase cGMP production, such as NO and natriuretic peptides, stimulate TH enzyme activity and gene transcription via activation of PKG. [7] [8] [9] [10] It is also of note that natriuretic peptides markedly increase the net content of intracellular catecholamine. 10 Stachowiak et al 11 previously showed that Ang II stimulates both TH enzyme activity and TH mRNA levels in rat adrenal medulla. However, the precise role of AT 1 and AT 2 in regulating catecholamine synthesis in adrenal medullary cells remains unclear.
Previously, we showed that activation of AT 2 negatively regulates catecholamine synthesis in cultured porcine chromaffin cells. 12 We 1 found that AT 2 is predominantly expressed in these cells 2 ; CGP 42112 (an AT 2 agonist, 1 nmol/L) significantly inhibited cGMP production to below basal levels 3 ; CGP 42112 (1 nmol/L) significantly inhibited both the enzyme activity of TH and mRNA and protein levels of TH; and pretreatment of cells with 8-Br-cGMP (a membrane-permeable cGMP analogue) prevented the inhibitory effect of CGP 42112 on TH enzyme activity. 4 To elucidate further the roles of AT 1 and AT 2 in catecholamine synthesis, we investigated the effect of Ang II alone (representing physiological conditions), Ang II plus CV-11974 (an AT 1 antagonist, selectively simulating AT 2 stimulation), and Ang II plus PD 123319 (an AT 2 antagonist, selectively simulating AT 1 stimulation) on the synthesis of catecholamine in cultured porcine adrenal medullary cells. In addition, we have examined the mechanisms underlying these effects on catecholamine synthesis.
Methods

Cell Culture
Cell culture, measurement of cGMP production, tyrosine hydroxylase enzyme activity, Northern blot analysis, Western blot analysis, and determination of intracellular levels were performed as described previously. [12] [13] [14] [15] 
PKC Activity
PKC activity was measured in cultured confluent cells as described previously. 16 
Gel Mobility Shift Assay
Nuclear extracts from cells were isolated as described previously. 17 An expanded Methods section can be found in an online data supplement available at http://www.hypertensionaha.org.
Results
Effect of Ang II Alone or Ang II Plus Either CV-11974 or PD 123319 on cGMP Production in Cultured Porcine Adrenal Medullary Cells
We have shown previously that CGP 42112 significantly inhibits cGMP production, as measured against basal levels, in cultured porcine adrenal medullary cells. 12 To further investigate these findings, we examined the effect of Ang II alone on cGMP production. As shown in Figure 1 , Ang II (1 nmol/L) inhibited cGMP production to levels significantly lower than the basal level. This inhibitory effect of Ang II on cGMP production was blocked by the co-addition of PD 123319 (an AT 2 antagonist, 1 or 100 nmol/L) but not of CV-11974 (an AT 1 antagonist, 1 or 100 nmol/L). Neither PD 123319 nor CV-11974 alone had significant effect on basal cGMP production. not affect PKC activity. PD 123319, CV-11974, and Ro-32-0432 alone did not affect basal PKC activity.
Effect of
Effects of Ang II Alone or Ang II Plus Either CV-11974 or PD 123319 on Ang II-Induced TH Enzyme Activity in Cultured Porcine Adrenal Medullary Cells
As shown in Figure 3a , Ang II alone (1 nmol/L) moderately but significantly increased TH enzyme activity to levels 1.3-fold higher than basal levels. Ang II plus 1 or 100 nmol/L CV-11974 significantly inhibited TH enzyme activity by 12% and 31%, respectively. In contrast, Ang II plus 1 or 100 nmol/L PD 123319 stimulated TH enzyme activity to levels Ϸ1.4-and 1.6-fold higher than basal levels, respectively. This stimulatory effect of AT 1 was completely inhibited by both the PKC inhibitor Ro-32-0432 ( Figure 3b ) and the MEK-1 inhibitor PD 98059 (Figure 3b ). PD 123319, CV-11974, Ro-32-0432, and PD 98059 alone had no significant effect on basal TH enzyme activity (Figure 3a and 3b ).
8-Br-cGMP and Phosphodiesterase Inhibitor Prevented the AT 2 -mediated Inhibitory Effect of TH Enzyme Activity
We investigated whether a decrease in cGMP production is involved in the inhibition of TH enzyme activity caused by stimulation of AT 2 . As shown in We examined the effect of Ang II alone or Ang II plus CV-11974 or PD 123319 on the levels of TH mRNA. As shown in Figure 4a and 4b, Ang II alone significantly stimulated TH mRNA production to levels 48% above the basal level. Ang II plus CV-11974 significantly inhibited production of TH mRNA to levels 20% below the basal level, whereas Ang II plus PD 123319 stimulated TH mRNA production to levels 71% above the basal level. Addition of either Ro-32-0432 or PD 98059 abolished the increase in TH mRNA levels induced by Ang II plus PD 123319. PD 123319, CV-11974, Ro-32-0432, and PD 98059 alone had no effect on basal TH mRNA level (data not shown).
Effects of Ang II Alone or Ang II Plus Either CV-11974 or PD 123319 on Levels of TH Protein and Intracellular Catecholamine
To confirm that there was a change in catecholamine synthesis following induction of TH mRNA, we examined the effects of Ang II plus CV-11974 or PD 123319 on TH protein production. Cells were treated with Ang II alone or with Ang II plus CV-11974 or PD 123319 for 24 hours. The levels of TH protein were then examined by Western blot analysis ( Figure 5 ). Ang II alone moderately but significantly increased levels of TH protein by 28%. Ang II plus CV-11974 significantly decreased levels of TH protein by 17%. In contrast, Ang II plus PD 123319 increased levels of TH protein by 47%. Neither PD 123319 nor CV-11974 alone affected on basal TH protein level. We also examined the intracellular levels of catecholamine. Cells were treated with Ang II plus either CV-11974 or PD 123319 for 24 hours, and the intracellular catecholamine levels were examined by high-performance liquid chromatography. As shown in Table  2 , Ang II plus CV-11974 significantly decreased intracellular catecholamine levels by 9.7%, whereas Ang II plus PD 123319 increased intracellular catecholamine levels by 10.0%. 
Effect of
Discussion
Here we have shown that the stimulation of AT 2 both inhibits production of cGMP ( Figure 1 ) and decreases TH enzyme activity below basal levels (Figure 3a ) in chromaffin cells.
Also, pretreatment of the cells with either 8-Br-cGMP or Zaprinast (a phosphodiesterase inhibitor) prevents this inhibitory effect of AT 2 (Table 1) . These results suggest that the inhibition of TH enzyme activity by AT 2 may be dependent on a decrease in cGMP production. As cGMP/PKG plays an important role in regulating TH enzyme activity, 6 -9 it is likely that AT 2 stimulation decreases the levels of cGMP, which in turn may reduce PKG activity, resulting in the inhibition of TH enzyme activity in chromaffin cells. AT 2 stimulation significantly reduced TH mRNA production to below the basal level (Figure 4 ). The precise mechanisms responsible for this AT 2 -mediated reduction in levels of TH mRNA are unclear. However, cGMP-inducing agents such as NO and natriuretic peptides also induce formation of an AP-1 complex composed of Fos/Jun dimmers, via activation of PKG. 19, 20 Jun and Fos proteins bind to the tetradecanoylphorbol 13-acetate-responsive elements (TRE) as homodimers or heterodimers. 21 Binding of the AP-1 (Fos/Jun) heterodimer to the TRE site of the TH promoter is a prerequisite for TH gene activation in PC12 cells. 22 Thus, we speculate that the decrease in TH gene expression induced by AT 2 stimulation is mediated through a reduction in transcription factor binding to the specific TRE site of the 5Ј-flanking region of the TH gene. In support of this hypothesis, we found that AT 2 stimulation induced a marked decrease in the binding activity of AP-1 (data not shown).
AT 2 stimulation also suppressed TH protein levels and intracellular catecholamine content ( Figure 5, Table 2 ), which indicates that AT 2 stimulation induces a decrease in TH gene expression, which in turn results in the decrease of the TH protein levels and intracellular net catecholamine content. Belloni et al 23 and we 24 recently demonstrated that AT 2 stimulation induces catecholamine release from the adrenal medulla. Thus, one explanation for the marked decrease observed in net catecholamine content is that AT 2 stimulation depletes catecholamine stores in 2 ways: (1) by stimulating catecholamine secretion and (2) by inhibiting catecholamine synthesis ( Figure 6 ).
In contrast to the inhibitory effects of AT 2 , AT 1 stimulated both TH enzyme activity, TH mRNA levels, and AP-1 binding activity in a PKC-as well as a MAPK-dependent manner (Figure 3, Figure 4) . Indeed, stimulation of AT 1 significantly upregulated PKC activity (Figure 2 ). Consistent with these findings, Raizada et al [25] [26] [27] recently demonstrated that AT 1 activation induces TH mRNA in both a PKC-and a MAPK-dependent manner through activation of AP-1-binding activity in rat brain neuronal cells.
It is believed that the effects of Ang II binding to the AT 1 are opposed by those of Ang II binding to the AT 2 in several systems, including cell proliferation and differentiation, angiogenesis, and chronotropic effects in the heart. 28 Along this line, we have shown here that AT 1 stimulation induces activation of catecholamine synthesis, whereas AT 2 stimulation inhibits catecholamine synthesis. These findings indicate that AT 2 and AT 1 appear to have counter-regulatory roles in the regulation of catecholamine synthesis. Also of note is that Ang II alone stimulates catecholamine synthesis, which suggests that under physiological conditions, AT 1 , as opposed to AT 2 , has a dominant regulatory role in catecholamine biosynthesis.
Recently, several AT 1 antagonists (AT 1 blockade: ARB) have been used to treat hypertension. Treatment with AT 1 antagonists increases plasma levels of Ang II, which subsequently stimulate AT 2 . It is of interest, therefore, that stimulating AT 2 significantly reduces the net intracellular content of catecholamine, probably through both inhibition of cate- cholamine synthesis and stimulation of catecholamine secretion, which may subsequently lead to catecholamine depletion and sympathoadrenergic inhibition. Thus, these findings raise the possibility that AT 1 antagonists may inhibit sympathoadrenergic activation following not only the suppression of AT 1 blocking properties but also the activation of AT 2 -a previously unknown, beneficial effect of its action ( Figure 6 ). Cells were incubated for 24 hr with DMEM (as a control), Ang II (1 nmol/L) alone, Ang IIϩCV-11974 (100 nmol/L) or Ang IIϩPD 123319 (100 nmol/L), and then the intracellular catecholamine (noradrenalineϩadrenaline) levels were measured as described in the Methods.
Values represent the meansϮSEM (nϭ4 -6). *Significantly different (PϽ0.05) from the basal level. 
